Engflag

Ostrid

Quick links to important sections

Ostrid

Ostrid_EN

Method of action: Antibacterials For Systemic Use, Bactericidal, Ophthalmologicals

Treatment option: Bronchitis, Influenza, Infection, Infection,Bacterial, Infection,Urinary Tract, Keratoconjunctivitis, COPD,Acute, Pneumonia, Mycoplasma Pneumonia, Prostatitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ostrid

Property Description
Active ingredient Ofloxacin
Pharmacological class Fluoroquinolone Antibiotic
Origin Synthetic compound
Form Tablet, Solution for Infusion, Topical Solutions
General purpose Elimination of bacterial pathogens

Ostrid: Definition and Pharmacological Class

Ostrid is a prescription-only medication whose active ingredient is Ofloxacin, and it is classified as a broad-spectrum antibiotic. It is fundamentally designed to fight and eliminate infections caused by susceptible bacteria.

Ostrid belongs to the fluoroquinolone group, which is a key pharmacological class of synthetic antimicrobial agents, distinguishing it from naturally derived antibiotics such as penicillin. The active ingredient acts as an antibacterial agent with effectiveness against a wide range of bacteria. This medicine addresses the root cause of systemic or local bacterial proliferation.

What Type of Medicine is Ostrid? Origin and Composition

The medicine contains only a single active compound, Ofloxacin, and operates as a bactericidal agent. This means the drug actively kills the target bacteria rather than merely halting their reproduction.

Ofloxacin operates through a specific mechanism of action. The composition of Ostrid is centered on this single active ingredient, a 4-Quinolone derivative, which is a synthetic compound. It achieves its effect by interfering with the bacteria's essential DNA synthesis and repair processes. This targeted, disruptive action reduces the bacterial load in the body, which is a key differentiator from agents that are merely bacteriostatic.

Available Forms and Preparations

Ostrid is prepared in various pharmaceutical forms, allowing for both systemic (whole-body) and localized administration. This versatility in formulation is a key aspect of Ofloxacin.

The available preparations include solid tablets for oral use and a sterile solution for infusion when the medication needs to be delivered intravenously. The flexibility extends to localized treatment through specialized liquid forms, such as ophthalmic solutions for the eye and otic solutions for the ear, ensuring targeted delivery to different infection sites.

Regulatory References

  1. DailyMed: Ofloxacin Ophthalmic Solution

What side effects are possible with Ostrid?

Ostrid (levocetirizine) is generally well-tolerated, but like all medications, it can cause side effects. These are usually mild and temporary.

Common Side Effects

The most frequently reported side effects include:

System Side Effect Rate
Neurological Drowsiness, Sleepiness, Headache, Dizziness Common
Gastrointestinal Dry mouth, Fatigue Common

If these effects persist or become bothersome, consult your healthcare provider.

Serious Side Effects

Rarely, more serious reactions such as hypersensitivity reactions (including swelling, rash, or difficulty breathing) or allergic reactions may occur. Seek immediate medical attention if you experience signs of a severe allergic reaction.

Safety Information and Warnings

  • Drowsiness Risk: Due to the potential for drowsiness and impaired alertness, exercise caution when driving or operating heavy machinery until you know how Ostrid affects you.
  • Alcohol Interaction: Avoid or limit alcohol consumption while taking Ostrid, as it may enhance the sedative effects and increase the risk of drowsiness.
  • Kidney Impairment: Ostrid is primarily eliminated by the kidneys. Patients with kidney problems should use this medication with caution, and a dose adjustment may be necessary. Always inform your doctor about any kidney-related health issues.
  • Contraindications: Ostrid is contraindicated in individuals with known hypersensitivity to levocetirizine, cetirizine, hydroxyzine, or any other component of the formulation. It is also generally not recommended for patients with severe kidney impairment or severe liver problems, or those with a predisposition to urinary retention.
  • Pregnancy and Breastfeeding: Discuss the use of Ostrid with a doctor if you are pregnant, planning to become pregnant, or breastfeeding, as limited data are available in these populations.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Ostrid (Ofloxacin) overdose outlines documented signs and mandates immediate emergency action due to the potential for severe systemic effects.

Documented Overdose Manifestations

Acute over-ingestion is officially documented to affect the Central Nervous System (CNS) and the Cardiovascular System. Manifestations may include CNS effects such as drowsiness, dizziness, confusion, and slurred speech, alongside gastrointestinal effects like nausea. Systemic signs documented in overdose cases include hot and cold flushes and numbness and swelling of the face.

Severe Outcomes and Emergency Action

Severe manifestations cited in regulatory documents include the potential for convulsions (seizures). The drug’s regulatory profile also cites the risk of ECG QT prolongation, which may lead to life-threatening ventricular arrhythmias such as Torsades de pointes, particularly in individuals with pre-existing risk factors. It is regulatory guidance that one must seek immediate medical attention for any suspected over-ingestion or acute symptoms. Urgent medical care and continuous ECG monitoring are required when severe neurological or cardiac events are suspected. No specific antidote is known for Ofloxacin overdose; therefore, management involves symptomatic treatment and supportive measures.

Therapeutic Uses of Ostrid

What Ostrid Treats: Main Uses and Benefits

Ostrid is commonly used for conditions marked by physiological stress, and may be used as part of symptomatic management in situations where patients experience distressing manifestations. Its therapeutic utility is focused on distinct domains where symptoms create noticeable physiological strain.

Ostrid is commonly used to help with symptoms related to inflammatory or irritative states in the urinary tract (UTIs), the reproductive system (e.g., chronic bacterial prostatitis and pelvic inflammatory disease), the lower respiratory tract (e.g., acute exacerbations of chronic bronchitis), and conditions involving the skin and skin structures.

It is also considered relevant for managing symptoms in localized contexts involving conditions that affect the eye (like bacterial conjunctivitis) and the ear (such as otitis externa). This helps address the overall symptom burden in conditions characterized by periods of heightened symptoms, and is used for managing symptom clusters that may become intense or disruptive.

Quick Fact: Relief for Painful Urination

The medication may assist with maintaining functional stability when symptoms interfere with daily comfort, and is applied in scenarios where additional symptomatic support is needed during acute or disruptive episodes.

Eligibility and Restrictions for Use

Absolute Contraindications

Ostrid must not be used by individuals with a known hypersensitivity to the active ingredient, ofloxacin, or any other medicine in the fluoroquinolone class. It is also contraindicated for patients with a history of tendon disorders related to prior fluoroquinolone exposure, as well as those with epilepsy or central nervous system disorders that lower the seizure threshold. The medicine is also formally contraindicated in patients with a history of Myasthenia Gravis.

Age and Reproductive Status

For systemic administration (tablets or infusion), Ostrid is generally contraindicated in children and growing adolescents. Eligibility for topical formulations (eye/ear drops) is established based on specific minimum age requirements documented in the regulatory label. Systemic use is officially contraindicated or highly restricted during pregnancy and breastfeeding.

Conditional Use and Restrictions

Use is conditional for patients with compromised organ function. Ostrid requires dosage adjustment for patients with impaired renal function. Caution is necessary for those with severe hepatic dysfunction and those with cardiovascular conditions that predispose to QT interval prolongation. Older adults are also identified as a population requiring caution due to increased risk of tendon problems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ostrid based on pharmacokinetic and pharmacodynamic constraints. These include mandatory rules for co-administration and specific restrictions for combination use.

Property Description
Medicinal product categories with documented interactions Antiarrhythmics, Corticosteroids, NSAIDs, Oral Hypoglycaemic Agents, Vitamin K Antagonists, Theophylline and related compounds, Metal Cation-Containing Preparations, Sucralfate, Drugs undergoing Renal Tubular Secretion.
Mechanistic basis of interactions (only if stated in label) Inhibition of gastrointestinal absorption; Competition for renal tubular clearance; Inhibition of metabolism; Additive pharmacodynamic effect (e.g., QTc prolongation).
Timing-based interaction rules (if applicable) Metal Cation-Containing Products (e.g., Iron Salts, Antacids, Calcium/Zinc Supplements) and Sucralfate must be administered at least 2 hours before or 2 hours after Ostrid tablets.

Official Interaction Statements

  • Antacids, iron salts, and Sucralfate significantly reduce the absorption of Ostrid, necessitating timing separation to maintain adequate systemic exposure.
  • Co-administration with Theophylline or NSAIDs is associated with a pronounced lowering of the cerebral seizure threshold.
  • Ostrid can increase the anticoagulant effect of Vitamin K Antagonists (e.g., Warfarin), which may increase the risk of bleeding.
  • Concomitant use with corticosteroids carries an increased risk of tendinitis and tendon rupture, with this risk being higher in the elderly population.
  • Ostrid presents an additive QTc prolongation risk when co-administered with other medicines known to affect the QTc interval, requiring caution.
  • The use of Ostrid with oral hypoglycaemic agents or insulin has been reported to cause hypoglycaemia, particularly in diabetic patients.
  • Ostrid may interfere with the renal tubular clearance of certain co-administered medicines (e.g., Probenecid), potentially increasing their serum levels.

These constraints establish the product's official risk profile, specifying required cautions for co-administration with agents that increase the risk of tendon injury, seizures, and bleeding, all based on documented regulatory findings.

Mechanism of Action

Targeted Inhibition of Cortisol Production

Ostrid's primary mechanism involves the direct competitive inhibition of the enzyme steroid 11-beta-hydroxylase (CYP11B1). This enzyme is localized in the adrenal cortex and executes the final step of the glucocorticoid synthesis pathway. By interrupting this process, Ostrid prevents the conversion of 11-deoxycortisol to cortisol, leading to a controlled reduction in the overall circulating cortisol levels and the modulation of systemic cortisol activity.

Modulation of Regulatory Feedback and Precursor Pathways

The resulting decrease in cortisol affects the Hypothalamic-Pituitary-Adrenal (HPA) axis, which is the body's central feedback loop governing glucocorticoid regulation. A secondary consequence of blocking the final synthesis step is the accumulation of precursor hormones, notably 11-deoxycortisol. The accumulation allows these precursors to interact with other receptors, producing secondary physiological effects such as the modulation of fluid and electrolyte balance.

Dosage and Administration Information

How to Use Ostrid: Administration Guidelines

Administration of Ostrid (Ofloxacin) is characterized by specific guidelines regarding dosing and frequency.

Category Instruction
Administration Routes Oral (Tablets), Intravenous (IV) (Solution for Infusion), and Topical (Ophthalmic and Otic solutions).
Standard Dosing Systemic dose range for adults is typically 200 mg to 400 mg per unit. The maximum total daily dose is 800 mg.
Frequency Doses are generally administered once or twice daily (every 12 hours), given at approximately equal intervals. Doses up to 400 mg may be given as a single dose.
Course Duration The length of therapy varies, from a 3-day course for specific uncomplicated infections to 6 weeks for chronic conditions like prostatitis. Treatment generally does not exceed 2 months.

Administration Conditions and Adjustments

  • Intake Rules: Oral tablets are taken with or without food. They are not to be taken within two hours of mineral antacids, sucralfate, or preparations containing metal cations (e.g., iron, zinc, aluminum, magnesium), as these can reduce Ostrid's absorption. The tablets are designed so they may be divided into equal doses.
  • Otic Preparation: The otic solution is typically warmed by holding the bottle in the hand for one to two minutes before instillation to minimize the risk of dizziness.
  • Renal Adjustment: Dosage is adjusted for patients with impaired kidney function (CrCl 50 mL/min). Following a standard initial dose, the maintenance dose is adjusted to 100 mg to 200 mg per day.
  • Missed Dose: If a dose is missed, standard protocol suggests taking it as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped to avoid doubling the dose.

Recent Clinical Evidence

Ostrid: Recent Clinical Evidence

Mechanism of Action

Research has evaluated the drug's proposed mechanism of action. Researchers hypothesized that the mechanism involves specific inflammatory pathways. Research has also explored the drug's interaction with specific biological markers.

Clinical Efficacy Studies

Knee Osteoarthritis (OA)

A series of randomized controlled trials (RCTs) and non-randomized studies have explored whether there is an association with changes in joint mobility in patients diagnosed with knee OA. Researchers investigated whether there was a correlation with a reduction in pain scores across various patient populations.

  • Primary Study 1 (RCT): This foundational study examined the drug's potential utility over a 12-week period in 300 patients with mild-to-moderate knee OA. The study design evaluated the time-course of potential response based on patient-reported pain and function assessments.
  • Study Findings: Outcomes reported a difference in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score when compared to the control group. The WOMAC index is a widely used patient-reported measure for evaluating pain, stiffness, and physical function in knee and hip OA.
  • Long-Term Data: An extended, open-label follow-up study examined the change in symptoms of knee osteoarthritis (OA) over the study period. This research focused on the durability of the observed responses.

Combination Therapy

Research has investigated whether the combination of the study drug with standard physical therapy is associated with changes in patient-reported function, compared to physical therapy alone. This approach was evaluated for use in long-term management.

Conclusion of Evidence

The drug represents an approach that has been the subject of research focused on joint discomfort, primarily in knee OA. Results indicated a difference when compared to placebo in some studies; however, findings regarding the drug's effect were mixed across different research populations. The full clinical significance of these findings remains under continuous review.

How should Ostrid be stored and disposed of?

How to Store and Dispose of Ostrid (Ofloxacin)

Storage and disposal requirements for Ostrid must align strictly with official regulatory documentation to maintain the product's quality and ensure safety.

Storage Conditions

Condition Requirement
Temperature Store tablets at mathbf20^circC to mathbf25^circC (mathbf68^circF to mathbf77^circF) (Controlled Room Temperature).
Protection Keep the medicine protected from excessive moisture and direct light; liquid forms must not be frozen.
Container Maintain the medicine in its original container or blister packaging, keeping the container tightly closed.
Child Safety The product must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired Ostrid should be discarded using an official drug take-back program as the primary method. If a take-back option is unavailable, the medicine must not be flushed down the toilet. Instead, it should be mixed with an unappealing substance (like used coffee grounds), sealed in a container, and placed in the household trash. Personal information must be removed from the packaging before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

Equivalent of Ostrid found in:

A-Z Index: